An experimental Alzheimer’s treatment slowed mental decline in patients with early stages of the disease by 34 percent, the first evidence that a medication may be able to alter the course of the disease, according to research presented by scientists meeting in Boston Monday. Scientists were quick to note that the results they found in their analysis of the drug, known as Solanezumab, were modest, and that more study needs to be done to confirm that the medication truly is effective.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help